Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Autologous bone marrow transplantation for CML].

F Nagamura1, T Nagamura-Inoue

  • 1Department of Safety and Ethical Evaluation, Research Hospital, Institute of Medical Science, University of Tokyo.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 5, 2002
PubMed
Summary

Autologous stem cell transplants are an experimental therapy for chronic myeloid leukemia (CML) when HLA-matched donors are unavailable. Research focuses on overcoming graft contamination and enhancing graft-versus-leukemia (GVL) effects for potential cures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.

Bone marrow transplantation·2015
Same author

Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2015
Same author

Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.

Bone marrow transplantation·2014
Same author

Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT.

Bone marrow transplantation·2013
Same author

Risk factors and organ involvement of chronic GVHD in Japan.

Bone marrow transplantation·2013

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Context:

  • Chronic myeloid leukemia (CML) treatment landscape.
  • Limitations of current first-line therapies like interferon-alpha (IFN-alpha) and allogeneic hematopoietic stem cell transplantation (HSCT).
  • The unmet need for alternative curative strategies in CML.

Purpose:

  • To explore the potential of autologous HSCT as a curative option for CML.
  • To address the challenges associated with autologous HSCT in CML, specifically graft contamination and lack of graft-versus-leukemia (GVL) effects.
  • To review strategies aimed at improving the efficacy of autologous HSCT for CML.

Summary:

  • Autologous HSCT is considered for CML patients lacking an HLA-matched donor, but faces significant hurdles.

Related Experiment Videos

  • Key challenges include the presence of Philadelphia chromosome-positive (Ph1-positive) cells in the graft and the absence of GVL effects.
  • Investigated approaches include optimizing stem cell collection, ex vivo purging techniques, cyclosporine administration for GVL, and post-transplant immunotherapy (IFN-alpha +/- Interleukin-2).

    • Impact:

    • Autologous HSCT remains a promising, albeit experimental, avenue for achieving a cure in CML.
    • Ongoing research into overcoming technical and immunological barriers could enhance its clinical applicability.
    • Successful implementation of autologous HSCT could expand treatment options for CML patients ineligible for allogeneic HSCT.